Effect of Sacubitril/Valsartan on the Right Ventricular Function and Pulmonary Hypertension in Patients With Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta-Analysis of Observational Studies

被引:29
|
作者
Zhang, Jing [1 ]
Du, Le [1 ]
Qin, Xiaohan [1 ]
Guo, Xiaoxiao [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Cardiol, Peking Union Med Coll Hosp, Beijing, Peoples R China
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2022年 / 11卷 / 09期
基金
中国国家自然科学基金;
关键词
heart failure; meta-analysis; pulmonary hypertension; right heart function; sacubitril/valsartan; NEPRILYSIN INHIBITION; DYSFUNCTION; MECHANISMS; PRESSURE;
D O I
10.1161/JAHA.121.024449
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Sacubitril/valsartan (SN) demonstrated significant effects in improving left ventricular performance and remodeling in patients with heart failure with reduced ejection fraction. However, its effects on the right ventricle remain unclear. This systematic review and meta-analysis aimed to assess the impact of S/V on right ventricular function and pulmonary hypertension. METHODS AND RESULTS: We searched PubMed, Embase, Cochrane Library, and Web of Science from January 2010 to April 2021 for studies reporting right ventricular and pulmonary pressure indexes following S/V treatment. The quality of included studies was assessed using the Newcastle-Ottawa scale. Variables were pooled using a random-effects model to estimate weighted mean differences with 95% CIs. We identified 10 eligible studies comprising 875 patients with heart failure with reduced ejection fraction (mean age, 62.2 years; 74.0% men), all of which were observational. Significant improvements on right ventricular function and pulmonary hypertension after S/V initiation were observed, including tricuspid annular plane systolic excursion (weighted mean difference, 1.26 mm; 95% CI, 0.33-2.18 mm; P=0.008), tricuspid annular peak systolic velocity (weighted mean difference, 0.85 cm/s; 95% CI, 0.25-1.45 cm/s; P=0.005), and systolic pulmonary arterial pressure (weighted mean difference, 7.21 mm Hg; 95% CI, 5.38-9.03 mm Hg; P<0.001). Besides, SN had a significant beneficial impact on left heart function, which was consistent with previous studies. The quadratic regression model revealed a certain correlation between tricuspid annular plane systolic excursion and left ventricular ejection fraction after excluding the inappropriate data (P=0.026). CONCLUSIONS: This meta-analysis verified that S/V could improve right ventricular performance and pulmonary hypertension in heart failure with reduced ejection fraction, which did not seem to be fully dependent on the reverse remodeling of left ventricle.
引用
收藏
页数:31
相关论文
共 50 条
  • [21] The effect of Sacubitril/Valsartan on cardiac function and cardiac remodeling in patients with heart failure with reduced ejection fraction
    Chen, Fangyuan
    Tian, Gang
    Bai, Xiaojun
    Li, Juanli
    Yuan, Zuyi
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (08) : 8684 - 8691
  • [22] Effect of sacubitril valsartan on cardiac function and endothelial function in patients with chronic heart failure with reduced ejection fraction
    Li, Bao-Hua
    Fang, Kuai-Fa
    Lin, Pei-Huan
    Zhang, Yi-Hui
    Huang, Yong-Xiang
    Jie, Hai
    CLINICAL HEMORHEOLOGY AND MICROCIRCULATION, 2021, 77 (04) : 425 - 433
  • [23] Left ventricular ejection fraction recovery in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan.
    Diez Villanueva, P.
    De la Cuerda, F.
    Vicent, L.
    Esteban-Fernandez, A.
    Gomez-Bueno, M.
    De Juan, J.
    Iniesta, A. M.
    Ayesta, A.
    Rojas, A.
    Bover, R.
    Iglesias, D.
    Garcia Aguado, M.
    Perea Egido, J. A.
    Salamanca, J.
    Martinez-Selles, M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 206 - 207
  • [24] Effectiveness of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Using Real-World Data: An Updated Systematic Review and Meta-Analysis
    Rahhal, Alaa
    Kasem, Mohamed
    Orabi, Bassant
    Hamou, Fatima
    Abuyousef, Safae
    Mahfouz, Ahmed
    Alyafei, Sumaya
    Shoukry, Ahmed Emad
    Ahmed, Emad
    CURRENT PROBLEMS IN CARDIOLOGY, 2023, 48 (01)
  • [25] Sacubitril/valsartan is associated with improved pulmonary haemodynamics in patients with heart failure with reduced ejection fraction
    Borrelli, C. Chiara
    Del Franco, A.
    Taddei, C.
    Chubuchny, V.
    Sciarrone, P.
    Gentile, F.
    Emdin, M.
    Passino, C.
    Giannoni, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 113 - 113
  • [26] Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis
    Gorter, Thomas M.
    Hoendermis, Elke S.
    van Veldhuisen, Dirk J.
    Voors, Adriaan A.
    Lam, Carolyn S. P.
    Geelhoed, Bastiaan
    Willems, Tineke P.
    van Melle, Joost P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (12) : 1472 - 1487
  • [27] LIVER FUNCTION AND PROGNOSIS, AND INFLUENCE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
    Suzuki, Kota
    Claggett, Brian
    Minamisawa, Masatoshi
    Packer, Milton
    Zile, Michael
    Rouleau, Jean L.
    Swedberg, Karl
    Lefkowitz, Martin
    Shi, Victor
    McMurray, John
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 800 - 800
  • [28] Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction
    Suzuki, Kota
    Claggett, Brian
    Minamisawa, Masatoshi
    Packer, Milton
    Zile, Michael R.
    Rouleau, Jean
    Swedberg, Karl
    Lefkowitz, Martin
    Shi, Victor
    McMurray, John J., V
    Zucker, Stephen D.
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (09) : 1662 - 1671
  • [29] Impact of Sacubitril–Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction
    Pere Pericas
    Caterina Mas-Lladó
    Maria Francisca Ramis-Barceló
    Isabel Valadrón
    Marta Noris Mora
    Lucía Pasamar Márquez
    Rosa González Colino
    José Francisco Forteza Albertí
    Vicente Peral Disdier
    Xavier Rossello
    High Blood Pressure & Cardiovascular Prevention, 2021, 28 : 167 - 175
  • [30] The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis
    Camila Hartmann
    Natasha Ludmila Bosch
    Luara de Aragão Miguita
    Elise Tierie
    Lídia Zytinski
    Cristina Pellegrino Baena
    International Journal of Clinical Pharmacy, 2018, 40 : 1443 - 1453